Evidence map›Paper›PMID 42328935›Full record

ArticleChannels (Austin, Tex.)2026

mTORC2-Na

Nolan M Dvorak, Jeffrey L Noebels

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Channels (Austin, Tex.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nolan M DvorakDevelopmental Neurogenetics Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
Jeffrey L NoebelsDevelopmental Neurogenetics Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.

Funding

PLASTICITY IN DEVELOPING EPILEPTIC BRAINR01NS029709 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI NOEBELS, JEFFREY · 1991 to 2025
$9.1M
Mechanism and role of mTORC2 in seizure reductionR01NS124145 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI JEANNIE CHIN, Jeffrey Noebels · 2022 to 2026
$2.8M
NINDS NIH HHS R01 NS029709NINDS NIH HHS R01 NS124145
6 · The paper itself

Abstract

Hyperexcitability is a biomarker of early-stage Alzheimer's Disease (AD) and hastens cognitive decline later in its course. Mechanistic target of rapamycin (mTOR) signaling contributes to the slope of this trajectory, as evidenced by early increased brain expression and the rescue of hyperexcitability by genetic deletion of mTOR complex 2 (mTORC2); however, a molecular mechanism directly linking mTOR signaling to membrane hyperexcitability in early-stage AD remains elusive. Here, we show that hyperactive mTOR signaling stimulates the voltage-gated Na

Indexed as

Alzheimer DiseaseMechanistic Target of Rapamycin Complex 2NAV1.2 Voltage-Gated Sodium ChannelSignal TransductionAnimalsDisease Models, AnimalHumansMiceMechanistic Target of Rapamycin Complex 2NAV1.2 Voltage-Gated Sodium ChannelAlzheimer’s diseasehyperexcitabilitymechanistic target of rapamycinpatch-clamp electrophysiologyVoltage-gated Na+ channel

Identifiers

PMID42328935
PMCPMC13290088

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.